Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study

PURPOSE: In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among > 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs). PATIENTS AND METHODS: Participants were ≤ 55 years of age at diagnosis,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Kerns, Sarah L., Fung, Chunkit, Monahan, Patrick O., Ardeshir-Rouhani-Fard, Shirin, Abu Zaid, Mohammad I., Williams, AnnaLynn M., Stump, Timothy E., Sesso, Howard D., Feldman, Darren R., Hamilton, Robert J., Vaughn, David J., Beard, Clair, Huddart, Robert A., Kim, Jeri, Kollmannsberger, Christian, Sahasrabudhe, Deepak M., Cook, Ryan, Fossa, Sophie D., Einhorn, Lawrence H., Travis, Lois B.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2018
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5959198/
https://ncbi.nlm.nih.gov/pubmed/29617189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.0735
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares